Home
About
Overview
Sharing Data
ORCID
Help
History (33)
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.
WD40 Repeats
MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations.
Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center.
See All 33 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center.
Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center. Dig Dis Sci. 2023 02; 68(2):385-388.
View in:
PubMed
subject areas
Arthritis, Rheumatoid
Colitis, Ulcerative
Crohn Disease
Heterocyclic Compounds, 3-Ring
Humans
authors with profiles
David Rubin